 NASHUA, N.H., March 03, 2021 GLOBE NEWSWIRE -- iCAD, Inc. the Company, NASDAQ: ICAD, a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the pricing of an underwritten public offering of 1,222,222 shares of its common stock at a public offering price of 18.00 per share. The gross proceeds of the offering to the Company are expected to be approximately 22.0 million, before deducting the underwriting discounts and commissions and other estimated offering expenses. In addition, the Company granted the underwriters a thirty-day option to purchase up to an additional 171,516 shares of common stock at the public offering price, less underwriting discounts and commissions. 